A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Piclidenoson (Primary) ; Apremilast
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COMFORT
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 27 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Aug 2018.
    • 07 Aug 2017 According to a Can-Fite BioPharma media release, this trial is expected to initiate in early 2018.
    • 07 Aug 2017 According to a Can-Fite BioPharma media release, based on the favorable safety data from cardiodynamic trial CTP#700287672 company is cleared to initiate this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top